AstraZeneca statement on results of ATLANTIC study of durvalumab in metastatic NSCLC
AstraZeneca has provided an update on preliminary findings from the ATLANTIC trial of durvalumab as 3rd-line or later stage therapy in patients with locally advanced or metastatic programmed death ligand-1 (PD-L1) positive non-small cell lung cancer (NSCLC) that lacks epidermal growth factor receptor (EGFR) or ALK alterations. An initial analysis supports durvalumab's clinical activity, with durable responses and an established safety profile in these difficult-to-treat patients.
ATLANTIC investigated the efficacy and tolerability of durvalumab in patients who received at least two prior systemic treatment regimens including platinum-based chemotherapy, and who have limited options for further therapy. A full evaluation of the data is ongoing and the results will be presented at a scientific congress in 2016.
AstraZeneca now believes it is unlikely that ATLANTIC can be used for regulatory submission as a monotherapy, but the company has said that will make that determination following a full analysis of the data.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins